Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, film coated - excipient ingredients: iron oxide red; povidone; meglumine; magnesium stearate; sodium hydroxide; lactose; iron oxide yellow; macrogol poly(vinyl alcohol) grafted polymer; citric acid monohydrate; colloidal anhydrous silica; lactose monohydrate; crospovidone - telmisartan/hct sandoz? is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: sodium starch glycollate type a; meglumine; lactose monohydrate; sodium hydroxide; maize starch; microcrystalline cellulose; mannitol; magnesium stearate; povidone; iron oxide red - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: microcrystalline cellulose; sodium hydroxide; maize starch; magnesium stearate; povidone; sodium starch glycollate type a; lactose monohydrate; meglumine; mannitol; iron oxide yellow - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: lactose monohydrate; mannitol; maize starch; sodium starch glycollate type a; povidone; magnesium stearate; sodium hydroxide; meglumine; microcrystalline cellulose; iron oxide red - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; povidone; sodium hydroxide; magnesium stearate; mannitol - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; magnesium stearate; mannitol; povidone; meglumine - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Malta - English - Malta Medicines Authority

brillpharma (ireland) limited inniscarra, main street, rathcoole, co. dublin, ireland - telmisartan - tablet - telmisartan 20 mg - agents acting on the renin-angiotensin system

Malta - English - Malta Medicines Authority

brillpharma (ireland) limited inniscarra, main street, rathcoole, co. dublin, ireland - telmisartan - tablet - telmisartan 40 mg - agents acting on the renin-angiotensin system

Malta - English - Malta Medicines Authority

brillpharma (ireland) limited inniscarra, main street, rathcoole, co. dublin, ireland - telmisartan - tablet - telmisartan 80 mg - agents acting on the renin-angiotensin system

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq) - telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of